Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2016

View Archived Issues

Shionogi recaps events of second quarter of fiscal 2016

Daiichi Sankyo reflects on achievements of second quarter of fiscal 2016

Eisai reviews pipeline highlights of second quarter of fiscal 2016

Sanofi offers overview of active third quarter 2016

Givinostat significantly counteracts histological disease progression in boys with DMD

Promising phase I/II results for PR1 peptide vaccine in patients with myeloid malignancies

Ruijin Hospital, Brandeis University and Xiamen University patent protein kinase inhibitors

Jiangsu Hengrui Medicine discloses IDO1 and/or TDO inhibitors

FDA awards orphan drug designation to Amryt's AP-102

FDA advisory committee votes on solithromycin submission for CABP

FDA approves Enbrel to treat children with moderate to severe plaque psoriasis

Genentech and Roche describe NMDA receptor modulators

Zucara Therapeutics receives investment from Canadian partners

University of British Columbia develops ERalpha antagonists

Researchers report new T2D risk loci in Jordan subpopulations

Cancer Research UK signs agreement with TYG Oncology

Pulmocide's PC-945 shows efficacy in mice

Apogenix achieves additional milestones under CANbridge Life Sciences deal

AdAlta and XL-protein collaborate to develop long-acting form of AD-114

Onxeo reports increased potency for Livatag compared with free doxorubicin

FDA grants orphan drug designation to veliparib

DCC mutations are associated with isolated ACC

MERIT study of macitentan in CTEPH meets primary endpoint

Aimmune Therapeutics wins equity investment from Nestle Health Science

Bayer seeks approvals for regorafenib in second-line HCC in U.S., E.U. and Japan

FDA clears IND for phase II trial of elafibranor in PBC

Bevacizumab-800CW tracer safe and tumor specific in cancer patients

Sandoz files application for approval of GP-2013 in Japan

EMA accepts MAA from Celltrion for CT-P6

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...